Tags

Type your tag names separated by a space and hit enter

Coffee, alcohol and other beverages in relation to cirrhosis mortality: the Singapore Chinese Health Study.

Abstract

Limited experimental and epidemiologic data suggest that coffee may reduce hepatic damage in chronic liver disease. The association between consumption of coffee and other beverages and risk of cirrhosis mortality was evaluated in the Singapore Chinese Health Study. This is a prospective population-based cohort of 63,275 middle-aged and older Chinese subjects who provided data on diet, lifestyle, and medical histories through in-person interviews using a structured questionnaire at enrollment between 1993 and 1998. Mortality from cirrhosis in the cohort was ascertained through linkage analysis with nationwide death registry. After a mean follow-up of 14.7 years, 114 subjects died from cirrhosis; 33 of them from viral hepatitis B (29%), two from hepatitis C (2%), and 14 from alcohol-related cirrhosis (12%). Compared to nondrinkers, daily alcohol drinkers had a strong dose-dependent positive association between amount of alcohol and risk of cirrhosis mortality. Conversely, there was a strong dose-dependent inverse association between coffee intake and risk of nonviral hepatitis-related cirrhosis mortality (P for trend = 0.014). Compared to non-daily coffee drinkers, those who drank two or more cups per day had a 66% reduction in mortality risk (hazard ratio [HR] = 0.34, 95% confidence interval [CI] = 0.14-0.81). However, coffee intake was not associated with hepatitis B-related cirrhosis mortality. The inverse relationship between caffeine intake and nonviral hepatitis-related cirrhosis mortality became null after adjustment for coffee drinking. The consumption of black tea, green tea, fruit juices, or soft drinks was not associated with risk of cirrhosis death.

CONCLUSION

This study demonstrates the protective effect of coffee on nonviral hepatitis-related cirrhosis mortality, and provides further impetus to evaluate coffee as a potential therapeutic agent in patients with cirrhosis.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Gastroenterology & Hepatology, Singapore General Hospital, Singapore.

    , , ,

    Source

    Hepatology (Baltimore, Md.) 60:2 2014 Aug pg 661-9

    MeSH

    Alcohol Drinking
    Asian Continental Ancestry Group
    Beverages
    Carbonated Beverages
    Coffee
    Feeding Behavior
    Female
    Humans
    Liver Cirrhosis
    Male
    Middle Aged
    Proportional Hazards Models
    Prospective Studies
    Risk Factors
    Singapore
    Tea

    Pub Type(s)

    Journal Article
    Research Support, N.I.H., Extramural

    Language

    eng

    PubMed ID

    24753005

    Citation

    Goh, George Boon-Bee, et al. "Coffee, Alcohol and Other Beverages in Relation to Cirrhosis Mortality: the Singapore Chinese Health Study." Hepatology (Baltimore, Md.), vol. 60, no. 2, 2014, pp. 661-9.
    Goh GB, Chow WC, Wang R, et al. Coffee, alcohol and other beverages in relation to cirrhosis mortality: the Singapore Chinese Health Study. Hepatology. 2014;60(2):661-9.
    Goh, G. B., Chow, W. C., Wang, R., Yuan, J. M., & Koh, W. P. (2014). Coffee, alcohol and other beverages in relation to cirrhosis mortality: the Singapore Chinese Health Study. Hepatology (Baltimore, Md.), 60(2), pp. 661-9. doi:10.1002/hep.27054.
    Goh GB, et al. Coffee, Alcohol and Other Beverages in Relation to Cirrhosis Mortality: the Singapore Chinese Health Study. Hepatology. 2014;60(2):661-9. PubMed PMID: 24753005.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Coffee, alcohol and other beverages in relation to cirrhosis mortality: the Singapore Chinese Health Study. AU - Goh,George Boon-Bee, AU - Chow,Wan-Cheng, AU - Wang,Renwei, AU - Yuan,Jian-Min, AU - Koh,Woon-Puay, Y1 - 2014/06/24/ PY - 2013/08/01/received PY - 2014/02/03/accepted PY - 2014/4/23/entrez PY - 2014/4/23/pubmed PY - 2014/9/23/medline SP - 661 EP - 9 JF - Hepatology (Baltimore, Md.) JO - Hepatology VL - 60 IS - 2 N2 - UNLABELLED: Limited experimental and epidemiologic data suggest that coffee may reduce hepatic damage in chronic liver disease. The association between consumption of coffee and other beverages and risk of cirrhosis mortality was evaluated in the Singapore Chinese Health Study. This is a prospective population-based cohort of 63,275 middle-aged and older Chinese subjects who provided data on diet, lifestyle, and medical histories through in-person interviews using a structured questionnaire at enrollment between 1993 and 1998. Mortality from cirrhosis in the cohort was ascertained through linkage analysis with nationwide death registry. After a mean follow-up of 14.7 years, 114 subjects died from cirrhosis; 33 of them from viral hepatitis B (29%), two from hepatitis C (2%), and 14 from alcohol-related cirrhosis (12%). Compared to nondrinkers, daily alcohol drinkers had a strong dose-dependent positive association between amount of alcohol and risk of cirrhosis mortality. Conversely, there was a strong dose-dependent inverse association between coffee intake and risk of nonviral hepatitis-related cirrhosis mortality (P for trend = 0.014). Compared to non-daily coffee drinkers, those who drank two or more cups per day had a 66% reduction in mortality risk (hazard ratio [HR] = 0.34, 95% confidence interval [CI] = 0.14-0.81). However, coffee intake was not associated with hepatitis B-related cirrhosis mortality. The inverse relationship between caffeine intake and nonviral hepatitis-related cirrhosis mortality became null after adjustment for coffee drinking. The consumption of black tea, green tea, fruit juices, or soft drinks was not associated with risk of cirrhosis death. CONCLUSION: This study demonstrates the protective effect of coffee on nonviral hepatitis-related cirrhosis mortality, and provides further impetus to evaluate coffee as a potential therapeutic agent in patients with cirrhosis. SN - 1527-3350 UR - https://www.unboundmedicine.com/medline/citation/24753005/full_citation L2 - https://doi.org/10.1002/hep.27054 DB - PRIME DP - Unbound Medicine ER -